Phase IB Study of Sorafenib and Evofosfamide in Patients with Advanced Hepatocellular and Renal Cell Carcinomas (NCCTG N1153, Alliance)

BACKGROUND: Sorafenib (Sor) remains a first-line option for hepatocellular carcinoma (HCC) or refractory renal cell carcinomas (RCC). PLC/PRF/5 HCC model showed upregulation of hypoxia with enhanced efficacy when Sor is combined with hypoxia-activated prodrug evofosfamide (Evo). METHODS: This phase...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Invest New Drugs
Main Authors: Tran, Nguyen H, Foster, Nathan R, Mahipal, Amit, Byrne, Thomas, Hubbard, Joleen, Silva, Alvin, Mody, Kabir, Alberts, Steven, Borad, Mitesh J.
Formato: Artigo
Idioma:Inglês
Publicado em: 2021
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC8282689/
https://ncbi.nlm.nih.gov/pubmed/33646489
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10637-021-01090-w
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados